Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of Nacubactam Alone and with Meropenem in Healthy Volunteers
NCT02972255Phase 1Completed
- Sponsor
- Roche
- Start
- Oct 2016
- Primary completion
- Mar 2017
- Modality
- Multivalent & Scaffold-Based Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Nacubactam in Gram-negative bacterial infection (6 arms), sponsored by Roche. Primary endpoints: Percentage of Participants With Adverse Events, Maximum Observed Plasma Concentration at Day 9 and 7 more. Started Oct 2016; status: completed.
02
Drugs
Nacubactam
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT02972255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02972255.